Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cyltezo® (adalimumab biosimilar) for the treatment of multiple c......
